Protara Therapeutics, Inc. Common Stock (TARA) Stock Price

TARAStock
$2.32−59.86%52W
Market Cap$137.10M
P/E—
PEG Ratio—
Div yield—
Beta1.55

TARA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-64.68%
Price vs S&P 500 (4W)-32.58%
VGM Score22.93

TARA Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$0.31-$0.36-14.64%(-$0.05)
Q1 2026-$0.37-$0.31+15.64%(+$0.06)
Q4 2025-$0.31-$0.38-21.81%(-$0.07)
Q3 2025-$0.39-$0.31+19.48%(+$0.08)
Q2 2025-$0.41-$0.35+15.32%(+$0.06)

TARA Analyst Recommendations

Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.14
4.14
4.14
4.14

Industry Peers — Biological Products(186)

SymbolValue ScoreGrowth ScoreMomentum ScoreP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
TARAProtara Therapeutics, Inc. Common Stock
——D————$2.32
AMGNAmgen IncDCA6.1x9.1%74.3%2.9%$432.49
GILDGilead Sciences IncCBA6.4x5.5%79.6%133.6%$156.19
MRNAModerna, Inc. Common StockFCA39.1x-27.6%36.4%—$218.01
ARGXargenx SE American Depositary SharesDAB6.6x165.2%89.8%—$819.14
RVMDRevolution Medicines, Inc. Common StockF—B3296.2x———$177.96
BIIBBiogen Inc. Common StockCDA3.4x0.3%74.0%-18.8%$232.65
BNTXBioNTech SE American Depositary ShareCCC7.6x-11.8%79.2%—$87.71
EXELExelixis IncCBA6.3x9.2%96.5%31.1%$62.23
HALOHalozyme Therapeutics, Inc.DBA8.3x41.1%82.4%22.9%$121.84
NBIXNeurocrine Biosciences IncCBB4.1x34.4%98.0%2.3%$135.71

About Protara Therapeutics, Inc. Common Stock

Protara Therapeutics develops transformative therapies for cancer and rare diseases with limited treatment options. The pipeline includes TARA-002 for lymphatic malformations and intravenous choline chloride for intestinal failure-associated liver disease (IFALD). The company focuses on underserved patient populations with significant unmet medical needs.